目的探究加强妊娠期糖尿病管理对妊娠期糖代谢异常患者的临床影响。方法将500例孕妇作为研究对象,按接收时间不同分为两个阶段,第1阶段250例为2010年1月-2013年1月,第2阶段250例为2013年2月-2015年12月;将两个阶段的孕妇分别分为两组,第1阶段235例糖代谢正常的为对照组,15例异常为实验组,第2阶段210例糖代谢正常的为对照组,40例异常为实验组;对第1阶段产妇进行血糖检查,对第2阶段产妇进行糖耐量测试并给予妊娠期糖尿病管理。结果第1段孕妇实验组新生儿黄疸、胎儿生长受限、妊娠期高血压疾病以及死胎等妊娠并发症发生率与对照组比较,差异无统计学意义(P>0.05),而早产、羊水过多、胎儿畸形、巨大胎儿等与对照组比较显著增高(P<0.05);第2段孕妇实验组新生儿黄疸、胎儿生长受限、妊娠期高血压疾病以及死胎、羊水过多、胎儿畸形、巨大胎儿等妊娠并发症与对照组比较,差异无统计学意义(P>0.05),而早产与对照组比较显著较高(P<0.05);第1阶段孕妇糖代谢异常率为6.00%,其中妊娠期糖尿病占2.00%、妊娠期糖耐量异常占1.60%、糖尿病合并妊娠占6.40%,第2阶段孕妇糖代谢异常率为16.00%,其中妊娠期糖尿病占6.40%、妊娠期糖耐量异常占6.00%、糖尿病合并妊娠占3.60%。结论对糖代谢异常的妊娠期孕妇实施妊娠期糖尿病管理,对妊娠结局有明显改善作用,且还可使妊娠并发症发生率降低,值得临床推广应用。 Objective To explore the clinical effect of strengthening management of gestational diabetes on patients with abnormal glucose metabolism during pregnancy. Methods 500 pregnant women were divided into two stages according to different receiving time. 250 patients in the first phase were from January 2010 to January 2013, and the second phase was 250 from February 2013 to December 2015 ; The two stages of pregnant women were divided into two groups, the first phase of 235 cases of normal glucose metabolism as the control group, 15 cases of abnormal experimental group, the second phase 210 cases of normal glucose metabolism as the control group, 40 cases were abnormal The experimental group; the first stage of maternal blood glucose test, the second stage of maternal glucose tolerance test and gestational diabetes management. Results The incidence of pregnancy complications such as neonatal jaundice, fetal growth restriction, gestational hypertension and stillbirth in experimental group 1 was not significantly different from that in control group (P> 0.05). However, preterm birth, amniotic fluid Fetal malformations and macrosomia were significantly increased compared with those in the control group (P <0.05). In the second experiment group, pregnant women suffered from jaundice, fetal growth restriction, gestational hypertension, stillbirth, polyhydramnios, fetal malformation, There were no significant differences in pregnancy complications between the giant fetus and the control group (P> 0.05), while the preterm birth was significantly higher than that of the control group (P <0.05). The abnormal glucose metabolism rate of the first stage pregnant women was 6.00% Gestational diabetes accounted for 2.00%, gestational glucose tolerance accounted for 1.60%, diabetes combined with pregnancy accounted for 6.40%, the second phase of pregnant women with abnormal glucose metabolism was 16.00%, of which gestational diabetes accounted for 6.40%, gestational glucose tolerance abnormalities accounted for 6.00 %, Diabetes combined pregnancy accounted for 3.60%. Conclusion Gestational diabetes management in pregnant women with abnormal glucose metabolism can improve the outcome of pregnancy and reduce the incidence of pregnancy complications, which is worthy of clinical application.